220903-33-3

Upstream product

• 621-59-0 isovanillin 
• 220903-32-2 (3S,6R)-3-(3-benzyloxy-2-chloro-4-methoxy)benzyl-6-isopropyl-2,5-bisethyl lactim ether 
• 210105-82-1 3-benzyloxy-2-chloro-4-methoxybenzyl bromide 
• 37687-57-3 2-chloro-3-hydroxy-4-methoxybenzaldehyde 
• 53713-77-2 3-benzyloxy-2-chloro-4-methoxy-benzaldehyde 
• 24424-99-5 di-tert-butyl dicarbonate 
• 110038-82-9 3-benzyloxy-2-chloro-4-methoxybenzyl alcohol 
• 100-39-0 benzyl bromide 

Downstream Products

• 778560-53-5 (S)-2-{[(S)-3-(3-Benzyloxy-2-chloro-4-methoxy-phenyl)-2-methylamino-propionyl]-methyl-amino}-3-phenyl-propionic acid allyl ester 
• 220903-37-7 N-tert-butyloxycarbonyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-(S)-phenylalanyl-N-methyl-(S)-phenylalanine allyl ester 
• 210105-85-4 (S)-N-tert-butyloxycarbonyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-phenylalanine 
• 210105-92-3 N-benzyloxycarbonyl-(O-benzyloxycarbonyl)-(R)-tyrosyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-(S)-phenylalanyl-N-methyl-(S)-phenylalanine-(R)-(piperazine-2,5-dione)methyl ester 
• 210105-90-1 N-benzyloxycarbonyl-(O-benzyloxycarbonyl)-(R)-tyrosyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-(S)-phenylalanyl-N-methyl-(S)-phenylalanine allyl ester 
• 210105-95-6 N-benzyloxycarbonyl-(O-benzyloxycarbonyl)-(R)-tyrosyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-(S)-phenylalanyl-N-methyl-(S)-phenylalanine 
• 147317-36-0 pepticinnamin E 
• 220903-34-4 (S)-N-tert-butyloxycarbonyl-(3-benzyloxy-2-chloro-4-methoxy)-phenylalanine 

Relevant academic research and scientific papers

Synthesis and in vitro evaluation of the farnesyltransferase inhibitor pepticinnamin E

The farnesyltransferase inhibitor pepticinnamin E was synthesized and shown to have the S configuration at the central, non-proteinogenic amino acid. Using a recombinant yeast farnesyltransferase the biological activity of the natural product and structur

Synthesis and in vitro evaluation of the Ras farnesyltransferase inhibitor pepticinnamin E

A modularly built bisubstrate inhibitor, the natural product pepticinnamin E (shown on the right) was synthesized for the first time. In the case of in vitro assays it inhibits the enzyme farnesyltransferase with respect to both the peptide substrate and farnesylpyrophosohate (K1 = 30 and 8 μM, respectively). The inhibitory activity is decisively influenced by the central tripeptide unit and the absolute configuration of the non-proteinogenic amino acid incorporated therein.